3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Head and Neck Neoplasms
7
Squamous Cell Carcinoma of Head and Neck
5
Oropharyngeal Neoplasms
3
Tongue Neoplasms
1
Thyroid Neoplasms
1
Radiation Injuries
1
Pain, Postoperative
1
Pain
1
Mucositis
1
Mouth Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma
1
Interventions
Cisplatin
55
Carboplatin
49
pembrolizumab
42
Paclitaxel
42
Gemcitabine
28
Pemetrexed
23
Radiotherapy
21
Magnetic Resonance Spectroscopy
20
Radiotherapy, Intensity-Modulated
18
Docetaxel
17
Cetuximab
17
Specimen Handling
16
Nivolumab
16
Fluorouracil
16
Cyclophosphamide
14
durvalumab
13
Bevacizumab
12
Radiation
11
Sorafenib
10
Platinum
10
130-nm albumin-bound paclitaxel
10
1,2-diaminocyclohexaneplatinum II citrate
10
osimertinib
9
Sunitinib
8
Oxaliplatin
8
Irinotecan
8
Ipilimumab
8
Everolimus
8
Drug Therapy
8
Capecitabine
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Carcinoma
×
Neck Dissection
×
Clear all
NCT05144100
2021-12-03
SCOPE
Tata Memorial Centre
Phase 2/3
Not yet recruiting
498 enrolled